25 XP   0   0   10

Mithra Pharmaceuticals SA
Buy, Hold or Sell?

Let's analyse Mithra together

PenkeI guess you are interested in Mithra Pharmaceuticals SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mithra Pharmaceuticals SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mithra Pharmaceuticals SA

I send you an email if I find something interesting about Mithra Pharmaceuticals SA.

Quick analysis of Mithra (30 sec.)










What can you expect buying and holding a share of Mithra? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
€0.50
Expected worth in 1 year
€0.49
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€-0.01
Return On Investment
-3.3%

For what price can you sell your share?

Current Price per Share
€0.28
Expected price per share
€0.201 - €1.084
How sure are you?
50%

1. Valuation of Mithra (5 min.)




Live pricePrice per Share (EOD)

€0.28

Intrinsic Value Per Share

€-16.11 - €-12.25

Total Value Per Share

€-15.61 - €-11.74

2. Growth of Mithra (5 min.)




Is Mithra growing?

Current yearPrevious yearGrowGrow %
How rich?$36.4m$36.6m-$165.5k-0.5%

How much money is Mithra making?

Current yearPrevious yearGrowGrow %
Making money-$64.4m-$126.4m$61.9m96.0%
Net Profit Margin-89.0%-515.6%--

How much money comes from the company's main activities?

3. Financial Health of Mithra (5 min.)




What can you expect buying and holding a share of Mithra? (5 min.)

Welcome investor! Mithra's management wants to use your money to grow the business. In return you get a share of Mithra.

What can you expect buying and holding a share of Mithra?

First you should know what it really means to hold a share of Mithra. And how you can make/lose money.

Speculation

The Price per Share of Mithra is €0.279. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mithra.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mithra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.50. Based on the TTM, the Book Value Change Per Share is €0.00 per quarter. Based on the YOY, the Book Value Change Per Share is €-1.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mithra.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.96-345.5%-0.96-345.5%-1.89-677.2%-0.99-356.4%-0.63-227.1%
Usd Book Value Change Per Share0.00-0.9%0.00-0.9%-2.00-717.9%-0.17-61.6%0.0518.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.001.6%
Usd Total Gains Per Share0.00-0.9%0.00-0.9%-2.00-717.9%-0.17-61.6%0.0620.0%
Usd Price Per Share3.68-3.68-21.61-19.33-12.85-
Price to Earnings Ratio-3.82--3.82--11.44--40.79--31.03-
Price-to-Total Gains Ratio-1,489.04--1,489.04--10.79--314.86--212.28-
Price to Book Ratio6.76-6.76-39.50-14.85-9.40-
Price-to-Total Gains Ratio-1,489.04--1,489.04--10.79--314.86--212.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.3017943
Number of shares3313
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.17
Usd Total Gains Per Share0.00-0.17
Gains per Quarter (3313 shares)-8.19-569.83
Gains per Year (3313 shares)-32.78-2,279.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-33-430-2279-2289
20-66-760-4559-4568
30-98-1090-6838-6847
40-131-1420-9117-9126
50-164-1750-11397-11405
60-197-2080-13676-13684
70-229-2410-15955-15963
80-262-2740-18235-18242
90-295-3070-20514-20521
100-328-3400-22793-22800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%6.05.00.054.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%2.00.08.020.0%2.00.09.018.2%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%6.05.00.054.5%

Fundamentals of Mithra

About Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Fundamental data was last updated by Penke on 2024-03-19 06:00:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Mithra Pharmaceuticals SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mithra earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -89.0% means that €-0.89 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -89.0%. The company is making a huge loss. -2
  • The TTM is -89.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-89.0%TTM-89.0%0.0%
TTM-89.0%YOY-515.6%+426.6%
TTM-89.0%5Y-339.9%+250.9%
5Y-339.9%10Y-204.8%-135.1%
1.1.2. Return on Assets

Shows how efficient Mithra is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • -13.5% Return on Assets means that Mithra generated €-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mithra Pharmaceuticals SA:

  • The MRQ is -13.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-13.5%0.0%
TTM-13.5%YOY-27.7%+14.2%
TTM-13.5%5Y-14.7%+1.2%
5Y-14.7%10Y-14.4%-0.2%
1.1.3. Return on Equity

Shows how efficient Mithra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • -177.0% Return on Equity means Mithra generated €-1.77 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mithra Pharmaceuticals SA:

  • The MRQ is -177.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -177.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-177.0%TTM-177.0%0.0%
TTM-177.0%YOY-345.4%+168.4%
TTM-177.0%5Y-123.1%-53.9%
5Y-123.1%10Y-96.8%-26.2%

1.2. Operating Efficiency of Mithra Pharmaceuticals SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mithra is operating .

  • Measures how much profit Mithra makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -49.9% means the company generated €-0.50  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -49.9%. The company is operating very inefficient. -2
  • The TTM is -49.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-49.9%TTM-49.9%0.0%
TTM-49.9%YOY-408.9%+359.0%
TTM-49.9%5Y-282.5%+232.6%
5Y-282.5%10Y-181.7%-100.8%
1.2.2. Operating Ratio

Measures how efficient Mithra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are €1.50 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.499. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.499. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.499TTM1.4990.000
TTM1.499YOY5.089-3.590
TTM1.4995Y3.825-2.326
5Y3.82510Y2.741+1.085

1.3. Liquidity of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mithra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.12 means the company has €1.12 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.118. The company is just able to pay all its short-term debts.
  • The TTM is 1.118. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.118TTM1.1180.000
TTM1.118YOY1.038+0.081
TTM1.1185Y2.340-1.222
5Y2.34010Y1.966+0.374
1.3.2. Quick Ratio

Measures if Mithra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.67 means the company can pay off €0.67 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.675. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.675. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.675TTM0.6750.000
TTM0.675YOY0.457+0.217
TTM0.6755Y1.806-1.132
5Y1.80610Y2.024-0.218

1.4. Solvency of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mithra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mithra to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.92 means that Mithra assets are financed with 92.4% credit (debt) and the remaining percentage (100% - 92.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.924. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.924. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.924TTM0.9240.000
TTM0.924YOY0.920+0.004
TTM0.9245Y0.741+0.183
5Y0.74110Y0.689+0.052
1.4.2. Debt to Equity Ratio

Measures if Mithra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,213.3% means that company has €12.13 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 12.133. The company is unable to pay all its debts with equity. -1
  • The TTM is 12.133. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ12.133TTM12.1330.000
TTM12.133YOY11.468+0.665
TTM12.1335Y5.741+6.393
5Y5.74110Y4.582+1.158

2. Market Valuation of Mithra Pharmaceuticals SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Mithra generates.

  • Above 15 is considered overpriced but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.82 means the investor is paying €-3.82 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -0.313. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.821. Based on the earnings, the company is expensive. -2
  • The TTM is -3.821. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.313MRQ-3.821+3.508
MRQ-3.821TTM-3.8210.000
TTM-3.821YOY-11.438+7.617
TTM-3.8215Y-40.791+36.970
5Y-40.79110Y-31.026-9.765
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -0.202. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.467. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.467. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.202MRQ-2.467+2.265
MRQ-2.467TTM-2.4670.000
TTM-2.467YOY-12.455+9.988
TTM-2.4675Y-51.800+49.333
5Y-51.80010Y-31.150-20.650
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mithra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 6.76 means the investor is paying €6.76 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is 0.554. Based on the equity, the company is cheap. +2
  • The MRQ is 6.763. Based on the equity, the company is overpriced. -1
  • The TTM is 6.763. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD0.554MRQ6.763-6.209
MRQ6.763TTM6.7630.000
TTM6.763YOY39.504-32.741
TTM6.7635Y14.850-8.087
5Y14.85010Y9.401+5.449
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mithra Pharmaceuticals SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.0020%-1.852+80878%-0.159+6854%0.047-105%
Book Value Per Share--0.5030.5030%0.5060%1.613-69%1.278-61%
Current Ratio--1.1181.1180%1.038+8%2.340-52%1.966-43%
Debt To Asset Ratio--0.9240.9240%0.920+0%0.741+25%0.689+34%
Debt To Equity Ratio--12.13312.1330%11.468+6%5.741+111%4.582+165%
Dividend Per Share----0%-0%-0%0.004-100%
Eps---0.891-0.8910%-1.747+96%-0.919+3%-0.586-34%
Free Cash Flow Per Share---1.380-1.3800%-1.604+16%-1.111-20%-0.736-47%
Free Cash Flow To Equity Per Share---0.069-0.0690%-1.081+1470%0.044-255%0.131-153%
Gross Profit Margin--1.0351.0350%1.016+2%1.0390%1.364-24%
Intrinsic Value_10Y_max---12.247--------
Intrinsic Value_10Y_min---16.109--------
Intrinsic Value_1Y_max---0.843--------
Intrinsic Value_1Y_min---1.538--------
Intrinsic Value_3Y_max---2.827--------
Intrinsic Value_3Y_min---4.715--------
Intrinsic Value_5Y_max---5.163--------
Intrinsic Value_5Y_min---7.969--------
Market Cap18667443.600-1120%227823102.000227823102.0000%1336829832.000-83%1195586199.600-81%795139425.600-71%
Net Profit Margin---0.890-0.8900%-5.156+479%-3.399+282%-2.048+130%
Operating Margin---0.499-0.4990%-4.089+719%-2.825+466%-1.817+264%
Operating Ratio--1.4991.4990%5.089-71%3.825-61%2.741-45%
Pb Ratio0.554-1120%6.7636.7630%39.504-83%14.850-54%9.401-28%
Pe Ratio-0.313+92%-3.821-3.8210%-11.438+199%-40.791+967%-31.026+712%
Price Per Share0.279-1120%3.4053.4050%19.980-83%17.869-81%11.884-71%
Price To Free Cash Flow Ratio-0.202+92%-2.467-2.4670%-12.455+405%-51.800+2000%-31.150+1163%
Price To Total Gains Ratio-122.009+92%-1489.040-1489.0400%-10.790-99%-314.862-79%-212.280-86%
Quick Ratio--0.6750.6750%0.457+48%1.806-63%2.024-67%
Return On Assets---0.135-0.1350%-0.277+106%-0.147+9%-0.144+7%
Return On Equity---1.770-1.7700%-3.454+95%-1.231-30%-0.968-45%
Total Gains Per Share---0.002-0.0020%-1.852+80878%-0.159+6854%0.051-104%
Usd Book Value--36439227.90036439227.9000%36604728.0000%116705694.700-69%92459172.860-61%
Usd Book Value Change Per Share---0.002-0.0020%-2.003+80878%-0.172+6854%0.051-105%
Usd Book Value Per Share--0.5450.5450%0.5470%1.744-69%1.382-61%
Usd Dividend Per Share----0%-0%-0%0.004-100%
Usd Eps---0.964-0.9640%-1.890+96%-0.994+3%-0.634-34%
Usd Free Cash Flow---99883096.300-99883096.3000%-116103187.800+16%-80389780.600-20%-53235865.500-47%
Usd Free Cash Flow Per Share---1.493-1.4930%-1.735+16%-1.201-20%-0.796-47%
Usd Free Cash Flow To Equity Per Share---0.074-0.0740%-1.169+1470%0.048-255%0.141-153%
Usd Market Cap20192573.742-1120%246436249.433246436249.4330%1446048829.274-83%1293265592.107-81%860102316.672-71%
Usd Price Per Share0.302-1120%3.6833.6830%21.612-83%19.329-81%12.855-71%
Usd Profit---64490954.000-64490954.0000%-126423687.500+96%-69823951.340+8%-44952531.410-30%
Usd Revenue--72470654.90072470654.9000%24519975.600+196%54753706.940+32%40992211.370+77%
Usd Total Gains Per Share---0.002-0.0020%-2.003+80878%-0.172+6854%0.056-104%
 EOD+3 -5MRQTTM+0 -0YOY+23 -115Y+14 -2010Y+7 -29

3.2. Fundamental Score

Let's check the fundamental score of Mithra Pharmaceuticals SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.313
Price to Book Ratio (EOD)Between0-10.554
Net Profit Margin (MRQ)Greater than0-0.890
Operating Margin (MRQ)Greater than0-0.499
Quick Ratio (MRQ)Greater than10.675
Current Ratio (MRQ)Greater than11.118
Debt to Asset Ratio (MRQ)Less than10.924
Debt to Equity Ratio (MRQ)Less than112.133
Return on Equity (MRQ)Greater than0.15-1.770
Return on Assets (MRQ)Greater than0.05-0.135
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Mithra Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.297
Ma 20Greater thanMa 500.278
Ma 50Greater thanMa 1000.580
Ma 100Greater thanMa 2000.891
OpenGreater thanClose0.279
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Other Assets  47,93556,007103,942-103,941101-2-1
Tax Provision  -9,8854,757-5,128-13,707-18,83511,940-6,89555,03448,139
Income Tax Expense  -9,8853,436-6,449-14,251-20,70011,238-9,46255,52146,059
Total Other Income Expense Net -51,679-1,751-53,43030,897-22,533-11,118-33,65153,53219,881



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets286,546
Total Liabilities389,803
Total Stockholder Equity-103,255
 As reported
Total Liabilities 389,803
Total Stockholder Equity+ -103,255
Total Assets = 286,546

Assets

Total Assets286,546
Total Current Assets93,408
Long-term Assets193,138
Total Current Assets
Cash And Cash Equivalents 8,980
Net Receivables 36,092
Inventory 48,289
Other Current Assets 47
Total Current Assets  (as reported)93,408
Total Current Assets  (calculated)93,408
+/-0
Long-term Assets
Property Plant Equipment 51,488
Goodwill 5,233
Long-term Assets Other 118,934
Long-term Assets  (as reported)193,138
Long-term Assets  (calculated)175,655
+/- 17,483

Liabilities & Shareholders' Equity

Total Current Liabilities103,981
Long-term Liabilities285,822
Total Stockholder Equity-103,255
Total Current Liabilities
Short-term Debt 26,703
Accounts payable 59,072
Other Current Liabilities 15,699
Total Current Liabilities  (as reported)103,981
Total Current Liabilities  (calculated)101,474
+/- 2,507
Long-term Liabilities
Long-term Liabilities  (as reported)285,822
Long-term Liabilities  (calculated)0
+/- 285,822
Total Stockholder Equity
Common Stock50,594
Retained Earnings -589,294
Accumulated Other Comprehensive Income 10,586
Other Stockholders Equity 424,859
Total Stockholder Equity (as reported)-103,255
Total Stockholder Equity (calculated)-103,255
+/-0
Other
Cash and Short Term Investments 8,980
Current Deferred Revenue2,507
Liabilities and Stockholders Equity 286,546
Net Debt 196,884
Short Long Term Debt Total 205,864



Balance Sheet

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
1,551
2,716
3,050
3,676
5,814
7,451
7,249
13,984
13,543
9,648
11,904
61,019
205,587
172,696
244,712
355,684
397,643
521,985
421,918
442,414
286,546
286,546442,414421,918521,985397,643355,684244,712172,696205,58761,01911,9049,64813,54313,9847,2497,4515,8143,6763,0502,7161,551
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
6,272
8,103
8,682
109,089
57,876
74,212
153,667
91,522
238,475
99,389
145,863
93,408
93,408145,86399,389238,47591,522153,66774,21257,876109,0898,6828,1036,272000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
703
1,561
2,113
7,794
2,150
36,190
118,949
49,720
138,675
32,872
28,285
8,980
8,98028,28532,872138,67549,720118,94936,1902,1507,7942,1131,561703000000000
       Short-term Investments 
598
784
262
974
505
636
1,013
460
158
0
0
0
89,000
43,600
0
0
46
14
-9,312
-2,886
0
0-2,886-9,31214460043,60089,0000001584601,013636505974262784598
       Net Receivables 
137
977
1,767
1,289
2,753
3,617
2,483
8,345
5,734
3,146
4,112
3,367
5,951
6,840
31,699
7,914
25,480
59,957
20,253
62,596
36,092
36,09262,59620,25359,95725,4807,91431,6996,8405,9513,3674,1123,1465,7348,3452,4833,6172,7531,2891,767977137
       Other Current Assets 
0
0
0
0
0
0
0
87
135
3,157
4,129
4,806
9,498
7,956
33,881
1,508
3,046
4,449
2,412
4,670
47
474,6702,4124,4493,0461,50833,8817,9569,4984,8064,1293,157135870000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
3,376
3,801
52,337
96,498
114,820
170,500
202,017
306,121
283,510
322,529
296,551
193,138
193,138296,551322,529283,510306,121202,017170,500114,82096,49852,3373,8013,376000000000
       Property Plant Equipment 
35
95
164
237
1,051
1,213
1,131
1,054
1,134
1,069
1,456
2,440
3,574
16,961
59,520
84,396
94,037
99,493
107,676
106,251
51,488
51,488106,251107,67699,49394,03784,39659,52016,9613,5742,4401,4561,0691,1341,0541,1311,2131,0512371649535
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
3,814
8,016
5,233
5,233
5,233
5,233
5,233
5,233
5,233
5,233
5,2335,2335,2335,2335,2335,2335,2335,2338,0163,81400000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
214
2,119
198
165
0
0
22,860
0
0
0
0
000022,860001651982,1192140000000000
       Intangible Assets 
650
538
354
735
568
486
416
1,826
1,960
1,887
1,725
41,649
78,234
79,130
80,385
81,907
92,723
94,238
110,187
140,138
0
0140,138110,18794,23892,72381,90780,38579,13078,23441,6491,7251,8871,9601,826416486568735354538650
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
61
463
3,871
90,131
44,738
2,644
3,436
-370
946
3,990
4,252
118,934
118,9344,2523,990946-3703,4362,64444,73890,1313,87146361000000000
> Total Liabilities 
591
1,665
1,911
2,087
3,836
4,894
6,167
10,391
9,577
7,643
9,416
55,495
78,193
79,681
157,830
204,791
234,345
364,248
388,078
408,727
389,803
389,803408,727388,078364,248234,345204,791157,83079,68178,19355,4959,4167,6439,57710,3916,1674,8943,8362,0871,9111,665591
   > Total Current Liabilities 
293
1,439
1,721
1,516
2,802
3,908
4,541
7,853
7,615
6,315
8,177
28,916
34,540
27,705
52,217
36,081
47,800
70,747
95,793
130,431
103,981
103,981130,43195,79370,74747,80036,08152,21727,70534,54028,9168,1776,3157,6157,8534,5413,9082,8021,5161,7211,439293
       Short-term Debt 
0
0
0
0
0
0
0
0
0
3,597
3,446
23,214
17,854
6,955
16,237
12,578
13,272
18,792
53,128
52,411
26,703
26,70352,41153,12818,79213,27212,57816,2376,95517,85423,2143,4463,597000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
4,685
105
904
6,955
16,237
10,443
6,526
11,477
46,567
47,232
0
047,23246,56711,4776,52610,44316,2376,9559041054,6850000000000
       Accounts payable 
42
1,282
1,270
1,185
1,771
2,816
2,710
3,695
2,136
1,418
2,581
5,393
4,613
9,312
16,141
13,071
19,449
23,325
16,915
31,716
59,072
59,07231,71616,91523,32519,44913,07116,1419,3124,6135,3932,5811,4182,1363,6952,7102,8161,7711,1851,2701,28242
       Other Current Liabilities 
110
58
293
138
413
383
530
2,765
2,667
1,300
2,150
309
12,073
11,438
19,839
10,432
14,288
27,371
24,133
44,887
15,699
15,69944,88724,13327,37114,28810,43219,83911,43812,0733092,1501,3002,6672,76553038341313829358110
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,328
1,239
26,579
43,653
51,976
105,613
168,710
186,545
293,501
292,285
278,296
285,822
285,822278,296292,285293,501186,545168,710105,61351,97643,65326,5791,2391,328000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
29,183
39,987
48,736
67,370
64,784
0
0
0
0
000064,78467,37048,73639,98729,183000000000000
       Other Liabilities 
0
0
0
136
0
0
0
19
38
1
0
0
5,957
3,734
2,365
6,484
8,809
8,336
9,251
19,944
0
019,9449,2518,3368,8096,4842,3653,7345,9570013819000136000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,575
3,105
7,441
12,036
19,917
51,969
0
051,96919,91712,0367,4413,1051,57500000000000000
> Total Stockholder Equity
961
1,051
1,140
1,589
1,978
2,557
1,082
3,593
3,966
2,005
2,488
5,524
127,394
93,015
86,882
150,893
163,298
157,737
33,840
33,687
-103,255
-103,25533,68733,840157,737163,298150,89386,88293,015127,3945,5242,4882,0053,9663,5931,0822,5571,9781,5891,1401,051961
   Common Stock
1,919
3,136
3,153
3,376
3,380
3,380
3,480
2,480
2,480
2,480
5,041
3,107
22,613
22,613
25,036
26,925
28,649
31,271
32,250
41,228
50,594
50,59441,22832,25031,27128,64926,92525,03622,61322,6133,1075,0412,4802,4802,4803,4803,3803,3803,3763,1533,1361,919
   Retained Earnings Total Equity000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-545
-700
-1,036
-1,232
-1,604
-3,265
-5,617
3,424
13,690
-2,545
-19,934
10,586
10,586-19,934-2,54513,6903,424-5,617-3,265-1,604-1,232-1,036-700-545000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
122,830
122,830
148,279
221,587
259,529
0
0
0
0
0000259,529221,587148,279122,830122,830000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
545
700
11,607
124,037
124,390
151,485
227,142
258,898
332,535
340,769
408,647
424,859
424,859408,647340,769332,535258,898227,142151,485124,390124,03711,607700545000000000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue66,997
Cost of Revenue-31,563
Gross Profit35,43435,434
 
Operating Income (+$)
Gross Profit35,434
Operating Expense-68,876
Operating Income-33,442-33,442
 
Operating Expense (+$)
Research Development64,041
Selling General Administrative14,675
Selling And Marketing Expenses2,100
Operating Expense68,87680,816
 
Net Interest Income (+$)
Interest Income3,682
Interest Expense-17,031
Other Finance Cost-0
Net Interest Income-13,349
 
Pretax Income (+$)
Operating Income-33,442
Net Interest Income-13,349
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-13,561-53,323
EBIT - interestExpense = -50,473
-13,561
-42,589
Interest Expense17,031
Earnings Before Interest and Taxes (EBIT)-33,4423,470
Earnings Before Interest and Taxes (EBITDA)-21,502
 
After tax Income (+$)
Income Before Tax-13,561
Tax Provision-48,139
Net Income From Continuing Ops-59,620-61,700
Net Income-59,620
Net Income Applicable To Common Shares-59,620
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses100,439
Total Other Income/Expenses Net19,88113,349
 

Technical Analysis of Mithra
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mithra. The general trend of Mithra is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mithra's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mithra Pharmaceuticals SA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.5 < 0.546 < 1.084.

The bearish price targets are: 0.201.

Tweet this
Mithra Pharmaceuticals SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mithra Pharmaceuticals SA. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mithra Pharmaceuticals SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mithra Pharmaceuticals SA. The current macd is -0.0877333.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mithra price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mithra. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mithra price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Mithra Pharmaceuticals SA Daily Moving Average Convergence/Divergence (MACD) ChartMithra Pharmaceuticals SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mithra Pharmaceuticals SA. The current adx is 56.19.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Mithra shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Mithra Pharmaceuticals SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mithra Pharmaceuticals SA. The current sar is 0.3039517.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Mithra Pharmaceuticals SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mithra Pharmaceuticals SA. The current rsi is 33.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Mithra Pharmaceuticals SA Daily Relative Strength Index (RSI) ChartMithra Pharmaceuticals SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mithra Pharmaceuticals SA. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mithra price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Mithra Pharmaceuticals SA Daily Stochastic Oscillator ChartMithra Pharmaceuticals SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mithra Pharmaceuticals SA. The current cci is 1.7930927.

Mithra Pharmaceuticals SA Daily Commodity Channel Index (CCI) ChartMithra Pharmaceuticals SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mithra Pharmaceuticals SA. The current cmo is -9.91643896.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Mithra Pharmaceuticals SA Daily Chande Momentum Oscillator (CMO) ChartMithra Pharmaceuticals SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mithra Pharmaceuticals SA. The current willr is -10.34482759.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Mithra Pharmaceuticals SA Daily Williams %R ChartMithra Pharmaceuticals SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mithra Pharmaceuticals SA. The current atr is 0.03749558.

Mithra Pharmaceuticals SA Daily Average True Range (ATR) ChartMithra Pharmaceuticals SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mithra Pharmaceuticals SA. The current obv is -20,413,369.

Mithra Pharmaceuticals SA Daily On-Balance Volume (OBV) ChartMithra Pharmaceuticals SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mithra Pharmaceuticals SA. The current mfi is 50.39.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Mithra Pharmaceuticals SA Daily Money Flow Index (MFI) ChartMithra Pharmaceuticals SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mithra Pharmaceuticals SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Mithra Pharmaceuticals SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mithra Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.297
Ma 20Greater thanMa 500.278
Ma 50Greater thanMa 1000.580
Ma 100Greater thanMa 2000.891
OpenGreater thanClose0.279
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Mithra with someone you think should read this too:
  • Are you bullish or bearish on Mithra? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mithra? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mithra Pharmaceuticals SA

I send you an email if I find something interesting about Mithra Pharmaceuticals SA.


Comments

How you think about this?

Leave a comment

Stay informed about Mithra Pharmaceuticals SA.

Receive notifications about Mithra Pharmaceuticals SA in your mailbox!